Patients with atrial fibrillation (AF) had measurable structural retinal changes in a large international study.
Commentary|Articles|September 2, 2026
BL1332 clears phase 1b: Yehia Hashad, MD, on what's next
Author(s)Yehia Hashad, MD, Lucia Gambuzza
Yehia Hashad, MD, discusses BL1332's phase 1b pain data and what's ahead as the TRPV1 antagonist enters phase 2 in patients with PRK.
Advertisement
Advertisement
Ocular surface pain remains a persistent clinical challenge, with few therapies designed to interrupt the neurosensory pathways that drive it rather than address the underlying inflammation indirectly. Ophthalmology Times spoke with Yehia Hashad, MD, executive vice president of research and development and chief medical officer at Bausch + Lomb, about the company's investigational TRPV1 antagonist BL1332 and what a recent phase 1b capsaicin challenge study revealed about its mechanism.
Related to this article
Rheumatoid arthritis, is an autoimmune disorder, develops more often in women than men in a 3:1 ratio.
Sarah Cheng, MD, PhD, discusses findings on orbital tissue changes in thyroid eye disease after teprotumumab treatment.
An association has been identified between primary open-angle glaucoma and erectile dysfunction.
The epidemiology, inflammatory pathophysiology, diagnosis, and treatment of diabetic macular edema are discussed during Inflammatory Eye Disease Week.
CLARITY program data show significantly longer time to treatment failure and higher rates of steroid-free quiescence vs placebo.
Spectacle lenses with highly aspherical lenslets are safe and effective for reducing myopia progression in US children.
CHMP backs Accord Healthcare’s Lucentis biosimilar Fovlussea for nAMD, DMO, RVO and CNV ahead of an EC decision.
Advertisement
Advertisement